Captain T Cell

The company's core business revolves around the development of next-generation T-cell therapies. Its business model is centered on advancing its proprietary therapeutic candidates through preclinical and clinical trials to eventually achieve regulatory approval and commercialization. A significant milestone was achieved in May 2024, when Captain T Cell secured €8.5 million in a seed financing round from a syndicate of investors including i&i Biotech Fund, Brandenburg Kapital, and HIL-INVENT. This funding is allocated to moving its lead programs toward clinical trials and further developing its platform technologies.

Captain T Cell's technology features two primary platforms. The first is focused on creating efficacy-enhanced autologous TCR-T cells, which are engineered to have greater persistence and resilience within the hostile microenvironment of solid tumors. Its lead autologous candidate, CTC 127, is expected to enter first-in-human clinical studies in 2027. The second, its proprietary TCR-ALLO platform, is designed to produce allogeneic, or 'off-the-shelf', treatments. This allogeneic approach aims to provide more accessible and potentially lower-cost therapies applicable to a wider range of cancer indications. In June 2025, the company announced its residency in the Bayer Co.Lab incubator in Berlin to further accelerate its programs.